Results 131 to 140 of about 2,162 (171)
Some of the next articles are maybe not open access.
Remimazolam in neuroanesthesia
Current Opinion in AnaesthesiologyPurpose of review Remimazolam is a novel ultrashort-acting benzodiazepine that has recently gained attention for its potential benefits in neuroanesthesia. This review aims to critically assess the latest evidence regarding its hemodynamic properties, neurophysiological monitoring compatibility, and recovery profile while ...
Abramovich, Igor +2 more
openaire +3 more sources
Current Opinion in Anaesthesiology
Purpose of review Remimazolam represents a novel intravenous anesthetic agent whose use began in 2020. As a new ultrashort-acting benzodiazepine, it has unique pharmacokinetic properties, such as remifentanil, designed to be active and easily transformed into inactive metabolites by tissue esterases.
Milena, Stojanovic, Radmilo, Jankovic
openaire +2 more sources
Purpose of review Remimazolam represents a novel intravenous anesthetic agent whose use began in 2020. As a new ultrashort-acting benzodiazepine, it has unique pharmacokinetic properties, such as remifentanil, designed to be active and easily transformed into inactive metabolites by tissue esterases.
Milena, Stojanovic, Radmilo, Jankovic
openaire +2 more sources
An update on remimazolam and anaphylaxis
European Journal of Anaesthesiology, 2023International ...
openaire +3 more sources
Remimazolam: A Review in Procedural Sedation
Drugs, 2021Remimazolam (Byfavo™) is a benzodiazepine sedative that is indicated for the induction and maintenance of procedural sedation in adults. Remimazolam was efficacious in three phase III trials in patients requiring endoscopies. Significantly higher procedure success rates (composite of the completion of the procedure, top-up doses of study drug within ...
Arnold Lee, Matt Shirley
openaire +2 more sources
Drugs, 2020
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation.
openaire +2 more sources
Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation.
openaire +2 more sources
The Metabolism of the New Benzodiazepine Remimazolam
Current Drug MetabolismBackground:: Remimazolam (RMZ) is a novel ultrashort-acting benzodiazepine used for sedation by intravenous administration. The pharmacophore of RMZ includes a carboxyl ester group sensitive to esterase- mediated hydrolysis, which is the primary path of metabolic elimination.
Wolfgang Schmalix +3 more
openaire +2 more sources
Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment
British Journal of Anaesthesia, 2021, Pieter Colin, Thomas Stöhr
exaly